UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 510

Sortiert nach

Patient-reported outcomes in GOG 252: NRG Oncology Study of IV vs IP chemotherapy for ovarian, fallopian, or peritoneal carcinoma

Gynecologic oncology, 2016-06, Vol.141, p.208-208

2016

Volltextzugriff (PDF)

Regional-specific alterations in cell–cell junctions, cytoskeletal networks and myosin-mediated mechanical cues coordinate collectivity of movement of epithelial cells in response to injury

Experimental cell research, 2014-03, Vol.322 (1), p.133-148

2014

Volltextzugriff (PDF)

Complications and surgical staging of endometrial cancer with respect to obesity: A Gynecologic Oncology Group LAP2 ancillary data study

Gynecologic oncology, 2014-06, Vol.133, p.31-31

2014

Volltextzugriff (PDF)

Operative outcomes among a geriatric population of endometrial cancer patients: An ancillary data analysis of Gynecologic Oncology Group study LAP2

Gynecologic oncology, 2014-06, Vol.133, p.7-7

2014

Volltextzugriff (PDF)

The impact of obesity on pathologic features and survival with endometrial cancer: A Gynecologic Oncology Group (GOG) LAP2 ancillary data study

Gynecologic oncology, 2014-06, Vol.133, p.173-174

2014

Volltextzugriff (PDF)

Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?

Gynecologic oncology, 2012-04, Vol.125 (1), p.94-98

2012

Volltextzugriff (PDF)

GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer

Gynecologic oncology, 2016-06, Vol.141, p.6-7

2016

Volltextzugriff (PDF)

Identifying gynecologic oncology patients with high symptom burden

Gynecologic oncology, 2015-04, Vol.137, p.195-195

2015

Volltextzugriff (PDF)

Provision of “primary palliative care” by gynecologic oncologists

Gynecologic oncology, 2015-04, Vol.137, p.52-52

2015

Volltextzugriff (PDF)

Variations in patient preferences over side effects of treatments for ovarian cancer: Baseline results of a randomized controlled clinical trial

Gynecologic oncology, 2017-06, Vol.145, p.26-27

2017

Volltextzugriff (PDF)

Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: An ancillary study of GOG 262

Gynecologic oncology, 2017-06, Vol.145, p.68-68

2017

Volltextzugriff (PDF)

Patterns of recurrence and survival after randomization to laparoscopy versus laparotomy in women with high-grade uterine cancer: A Gynecologic Oncology Group (GOG) study

Gynecologic oncology, 2014-06, Vol.133, p.49-49

2014

Volltextzugriff (PDF)

A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG) study

Gynecologic oncology, 2015-05, Vol.138, p.3-3

2015

Volltextzugriff (PDF)

A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

Gynecologic oncology, 2015-04, Vol.137, p.3-4

2015

Volltextzugriff (PDF)

A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study

Gynecologic oncology, 2017-06, Vol.145, p.219-219

2017

Volltextzugriff (PDF)

Reducing Heart Failure Readmissions Among Post Open Heart Surgical Patients

Heart & lung, 2013-07, Vol.42 (4), p.307-308

2013

Volltextzugriff (PDF)

Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers

Gynecologic oncology, 2014-06, Vol.133, p.25-25

2014

Volltextzugriff (PDF)

Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262

Gynecologic oncology, 2014-06, Vol.133, p.58-58

2014

Volltextzugriff (PDF)

Patient and physician factors associated with participation in Gynecologic Oncology Group (GOG) trials in cervical and uterine cancer

Gynecologic oncology, 2014-06, Vol.133, p.39-40

2014

Volltextzugriff (PDF)

Applications of list decoding to tracing traitors

IEEE transactions on information theory, 2003-05, Vol.49 (5), p.1312-1318

2003

Volltextzugriff (PDF)

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

The New England journal of medicine, 2016-02, Vol.374 (8), p.738-748

2016

Volltextzugriff (PDF)

Patterns of Opioid Use in Gynecologic Oncology Surgical and Cancer Surveillance Patients

Gynecologic oncology, 2020-03, Vol.156 (3), p.e43-e43

2020

Volltextzugriff (PDF)

Comparison of postoperative opioid reduction strategies following gynecologic surgery

Gynecologic oncology, 2020-10, Vol.159, p.281-282

2020

Volltextzugriff (PDF)

Neoadjuvant chemotherapy: Patterns of utilization and predictors of surgical resectability

Gynecologic oncology, 2008-11, Vol.111 (2), p.381-382

2008

Volltextzugriff (PDF)

Chemotherapy in recurrent ovarian cancer: What clinical benefit should be expected?

Gynecologic oncology, 2008-11, Vol.111 (2), p.380-380

2008

Volltextzugriff (PDF)

1 – 25 von 510

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(437)
Mit Volltextzugriff
(455)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(320)
Life Sciences & Biomedicine
(182)
Physical Sciences
(116)
Humans
(89)
Physics
(84)
Technology
(68)
Biological And Medical Sciences
(65)
Astronomy & Astrophysics
(53)
Female
(52)
Male
(47)
Astrophysics
(42)
Fundamental And Applied Biological Sciences. Psychology
(42)
Engineering
(41)
Animals
(40)
Astronomy And Astrophysics
(38)
Hematology, Oncology And Palliative Medicine
(27)
Medical Sciences
(26)
Exact Sciences And Technology
(24)
Obstetrics And Gynecology
(24)
Middle Aged
(22)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Patient-reported outcomes in GOG 252: NRG Oncology Study of IV vs IP chemotherapy for ovarian, fallopian, or peritoneal carcinoma

Regional-specific alterations in cell–cell junctions, cytoskeletal networks and myosin-mediated mechanical cues coordinate collectivity of movement of epithelial cells in response to injury

Complications and surgical staging of endometrial cancer with respect to obesity: A Gynecologic Oncology Group LAP2 ancillary data study

Operative outcomes among a geriatric population of endometrial cancer patients: An ancillary data analysis of Gynecologic Oncology Group study LAP2

The impact of obesity on pathologic features and survival with endometrial cancer: A Gynecologic Oncology Group (GOG) LAP2 ancillary data study

Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?

GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer

Identifying gynecologic oncology patients with high symptom burden

Provision of “primary palliative care” by gynecologic oncologists

Variations in patient preferences over side effects of treatments for ovarian cancer: Baseline results of a randomized controlled clinical trial

Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: An ancillary study of GOG 262

Patterns of recurrence and survival after randomization to laparoscopy versus laparotomy in women with high-grade uterine cancer: A Gynecologic Oncology Group (GOG) study

A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG) study

A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study

Reducing Heart Failure Readmissions Among Post Open Heart Surgical Patients

Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers

Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262

Patient and physician factors associated with participation in Gynecologic Oncology Group (GOG) trials in cervical and uterine cancer

Applications of list decoding to tracing traitors

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Patterns of Opioid Use in Gynecologic Oncology Surgical and Cancer Surveillance Patients

Comparison of postoperative opioid reduction strategies following gynecologic surgery

Neoadjuvant chemotherapy: Patterns of utilization and predictors of surgical resectability

Chemotherapy in recurrent ovarian cancer: What clinical benefit should be expected?

Suchergebnisse filtern